MitchellGrossMD

Oncology • Los Angeles, CA

Genitourinary Oncology, Hematologic Oncology

USC Westside Cancer Center Center for Applied Molecular Medicine

Join to view full profile

Dr. Gross is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gross' full profile

Already have an account?

Office
12414 Exposition Blvd
Los Angeles, CA 90064
Phone+1 310-272-7640

Summary

Dr. Mitchell Gross is an oncologist in Beverly Hills, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, and LAC+USC Medical Center. He received his medical degree from Baylor College of Medicine and has been in practice 23 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in prostate cancer, urologic oncology, bladder cancer, testicular cancer, and pediatric urologic oncology.

Education & Training

UCLA, College of Letters and SciencePh.D, Molecular Biolog, 2003
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2002
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1994 - 1997
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1994 - 1995
Baylor College of MedicineClass of 1994
University of California BA, Biochemistry/Cell Biology, 1990

Certifications & Licensure

CA State Medical License 1996 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Specialty Training Research Fellowship 1997-2222, 2002
AACR-AFLAC Scholar in Training Award 2001
Amgen Fellowship Research Award 1999
Rhone Phoulenc Rorer Travel Award 1999
UCSD/Revelle College Academic Leadership Award 1994
HP Award for Excellence in Internal Medicine 1994
Alpha Omega Alpha 1994
Phi Beta Kappa 1989
Join now to see all

Clinical Trials

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer Start of enrollment: 2010 Feb 17
Completed
Phase 1, Phase 2
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer Start of enrollment: 2008 Apr 01
Terminated
Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Start of enrollment: 2014 Sep 08
Completed
Phase 2
Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors Start of enrollment: 2018 Dec 26
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

4 citations
MRI Detection of Lymph Node Metastasis through Molecular Targeting of C-C Chemokine Receptor Type 2 and Monocyte Hitchhiking.
Noah Trac, Zixi Chen, Hyun-Seok Oh, Leila Jones, Yi Huang
ACS Nano. 2024-01-23
4 citations
Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial.
Jacqueline K. Dawson, Tanya B. Dorff, Creighton T. Tuzon, Judd C. Rice, E T. Schroeder
Integrative Cancer Therapies. 2021-07-23
34 citations
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek Pinski, David I. Quinn
Prostate Cancer and Prostatic Diseases. 2021-03-01

Journal Articles

Defining the activity of second-line regimens in taxane refractory hormone refractory prostate cancer patients refractory to taxanes: a randomized phase II study of ix...
Rosenberg, J., Weinberb, V., Gross, M., Wilding, G., Hussain, M., Kelly, W.K., Hutcheon, D., Small, E, Cancer, 110:556-63
A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085).
Yu, E., Massard, C., Gross, M., Wilding, G., Posadas, E., Culine, S., Carducci, M. A., Trudel, G., Paliwal, P., Sternberg C, Proc. Amer. Soc. of Clin. Oncol., Abstract 5147
Androgen receptor and estrogen receptor-beta associates with Gleason score, but not obesity in prostate cancer.
Gross, M., Nepomuceno, E., Luthringer, D, Vollmer, R., Burchette, J., Freedland, S, Proc. Amer. Urol. Assoc, Abstract 1618
Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer.
Amato, R., Wilding, G., Bubley, G., Trudeau, C., Rivera, V.M.. Agus, D.B. Gross, M, Clin. Genitourin. Cancer 4:299-302
Body Image Predicts Quality of Life in Men with Prostate Cancer.
Taylor-Ford, M., Meyerowitz, B.E., D’Orazio, L.M., Christie,K.M., Gross, M.E., Agus, D.B, Psycho-Oncology
3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ul...
Ukimura, O., Desai, M.M., Palmer, S., Valenceria, S., Gross, M., Abreu, A.L., Aron, M., Gill, I.G, J. Urol. 187(3):1080-6
Show us a sign: the search for “game changing” prostate cancer biomarkers.
Quinn, D., Gross, M, Lancet Oncology, 12(3):204-6
Androgen Receptor Mutation Detection of Circulating Tumor Cells in Castration Resistant Prostate Cancer.
Jiang, Y., Palma, J., Agus, D.B., Wang, Y., Gross, M.E, Clinical Chemistry, 56(9):1492-5
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer (CRPC).
Yu E, Massard C, Gross M, Wilding G, Posadas E, Culine S, Carducci MA, Trudel G, Paliwal P, Sternberg C, Clin Canc Res 15:7421-7428
Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.
Gross, M., Ramirez, C., Luthringer, D., Nepomuceno, E., Vollmer, R., Burchette, J., Freedland, S.J, The Prostate, 69:520-7
Mechanisms of Emotional Adjustment following Treatment Decision-Making for Prostate Cancer: Conversations, Cognitive Processing, and Coping.
Christie,K., Meyerowitz, B., Giedzinska-Simons, A., Gross, M., Agus, D.B, Psycho-Oncology, 18: 508-14
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Gross, M., Higano, C., Pantuck A., Castellanos, O. Green E., Nguyen K., and D. B. Agus, BMC Cancer, 7:142
Role of AUUU sequences in stabilization of granuclocyte-macrophage colony-stimulating factor RNA in stimulated cells.
Akashi M., Shaw G., Gross M., Saito M., Koeffler H.P, Blood. 78:2005-12.
Beta-2-microglobulin is an Androgen-regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer.
Gross, M., Top, I., Laux, I., Katz, J., Curran, J., Tindell, C., Agus, D, Clin. Cancer Res., 13:1979-1986
Review of Metastasectomy for Isolated Bilateral Adrenal Metastases in Hormone-refractory Prostate Cancer.
Gross, M, Clin. Adv.Hemat. Oncol. 4:756-7
Phase II evaluation of cilengitide in asymptomatic patients with androgen-indpendent prostate cancer: scientific rationale and study design.
Beekman, K.W., Colevas, A.D., Cooney, K., Dipaola, R., Dunn, R.L., Gross, M., Keller, E.T., Ryan, C.J., Smith, D., Hussain, Clin. Genitourin. Cancer 4:299-302
Raloxifene, an ER-β targeted therapy, inhibits androgen independent prostate cancer growth: results from preclinical studies and a Phase II clinical trial.
Shazer, R., Galkin,A., Aronson, N., Nguyen, K., Cinman, N., Natale, R., Gross, M., Green, L., Bender, L., Holden, S., Kaplan, S., Agus, D.B, BJU Int. 97:691-7.
Protein Partners of C/EBPe.
Chih, D.Y., Park, D.J., Gross, M., Idos, G., Vuong, P.T., Hirama,T., Chumakov, A.M., Said, J., Koeffler, H.P, Exp Hematol. 32:1173-81
PIASy-mediated repression of the androgen receptor is independent of sumoylation.
Gross, M., Yang, R., Top, I., Gasper, C., Shuai, K, Oncogene. 23:3059-66
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells.
Gross, M., Liu, B., Tan, J-a., French, F.S., Carey, M., Shuai, K, Oncogene, 20: 3880-7
A transcriptional corepressor of Stat1 with an essential LXXLL signature motif.
Liu, B, Gross, M, ten Hoeve, J., Shuai, K, Proc. Natl. Acad. Sci. USA 98: 3203-3207
In vitro antimicrobial effect against Steptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or l-oflaxacin.
Giron K.P., Gross M.E., Musher D.M., Williams T.W. Jr, Antimicro. Agents Chemo. 39:2798-2800.
Antimicrobial activities of beta-lactam antibiotics and gentamycin against penicillin-susceptible and penicillin-resistant pneumococci.
Gross M.E., Giron K.P., Septimus J.D., Mason E.O., Musher D.M, Antimicro Agents Chemo. 39:1166-8
Lack of effect of clinical research protocol participation on morbidity measures in HIV-infected children.
Gross M.E., Smith E.O., Kline M.W, Ped. Infect Dis.J. 12:157-8
Join now to see all

Books/Book Chapters

The Molecular Cancer Handbook.
Chapter: Models for Prostate Cancer
Jain, A., Vashistha, S., Gross, M., Agus, DEditors: Jörg Haier.Edition 2,
Drug Management of Prostate Cancer.
Chapter: Applications of Proteomics in Prostate Cancer
Gross, M., Nepomuceno, E., Agus, DEditors: William Douglas Figg, Sr., Cindy H. Chau, and Eric J.Small, Springer Science + Business Media, New York

Abstracts/Posters

Beta-2-microglobulin: Potential for a therapeutic target expressed in aggressive prostate cancer.
Mink, S., Kwon G.Y., Luthringer, D.J., Amin, M.B., Agus, D.B. Gross, M, Proc. AACR Annual Meeting, Abstract 3019
Combinatory localize cytolysis with micron precision by acoustic transducer array for fast screening of drug induced cytoskeleton alteration.
Wang, L., Li, Y.-J., Lin, A., Choe, Y., Gross, M., and Kim, E.S, Proceedings of the 25th International Conference on Micro Electro Mechanical Systems (MEMS 2012), Pa
Non-enrichment based method for analysis of androgen receptor expression in circulating tumor cells in patients with metastatic castrate resistant prostate cancer.
Gross, M.E., Lazar, D., Cho, E.H., Luttgen, M., Metzner, T., Uson, M.L., Torrey, M.L., and Kuhn, P, American Society for Clinical Oncology Genitourinary Conference (ASCO GU 2012), San Francisco, Calif
Cell lysis by low power focused acoustic transducer and investigation of acoustic intensity threshold for cytolysis of various cell lines.
Wang, L., Li, Y.-J., Lin, A., Chen, S.-J., Gross, M., and Kim, E.S, 15th International Conference on Minaturized Systems for Chemistry and Life (MicroTAS 2011), Seattle
Evaluation of Circulating Tumor Cells in Chemotherapy-naieve Patients with Metastatic Castration-Resistant Prostate Cancer Receiving TAK-700.
Gross. M., Shevrin, D., Dreicer, R., Trpicchio, W.L., MacLean, D., Webb, I., Agus, D.B, Proc. Eur. Soc. Med. Oncol. Abstract 7.014
Safety, Efficacy, and Pharmacodynamics of the Iinvestigational Agent TAK-700 in Metastatic Castration-Resistant Prostate Cancer.
Agus, D.B., Stadler, W.M., Shevrin, D.H., MacVicar, G.R., Hamid, O., Hainsworth, S., Gross, M.E., Wang, J., de Leon, L., MacLean, D., Dreicer, R, Proc. Amer. Soc. of Clin. Oncol, Abstract 4531
Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC).
Gross, M. E., Soscia, J., Sakowsky, S., Castellanos, O., Agus D. B, Proc. Amer. Soc. of Clin. Oncol, Abstract 5154154.
Circulating Tumor Cell Enumeration Combined with Gene Expression Analysis and Clinical Variables in Castrate Resistant Prostate Cancer.
Gross, M, Agus, D, Palma, J., Wang, Y., Jiang, J, AACR Translational Oncology, Abstract B33
Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study.
Yu, E.Y., Wilding, G., Posadas, E., Gross, M., Culine, S., Massard, C., Hudes, G.R., Cheng, S., Paliwal, P., Sternberg C. N, Proc. Amer. Soc. of Clin. Oncol, Abstract 5156
Cilengitide in asymptomatic metastatic androgen independent prostate cancer (AIPC) patients (pts): A randomized phase II trial.
Bradley, D. A., Daignault, S., Ryan, C., DiPaola, R.P., Smith, D.C., Mathew P., Gross, M., Chen, A. P., Keller, E. T., Hussain M. H, Proc. Amer. Soc. of Clin. Oncol, Abstract 5144
TPI 287, a third-generation taxane, is active and well tolerated as 2nd line therapy after failure of docetaxel in hormone refractory prostate cancer (HRPC).
Gross, M., Pendergrass, K., Leitner, S., Leichman, G., Pugliese, L., Silberman S, Proc. Amer. Soc. of Clin. Onco, Abstract 16130l
Androgen receptor and estrogen receptor-beta associates with Gleason score, but not obesity in prostate cancer.
Mitchell E, American Urological Association, Anaheim, California
Health Related Quality of Life Correlates of the Treatment Decision-Making Process of Newly Diagnosed Prostate Cancer Patients.
Giedzinksa-Simons AS, Christie KM, Meyerowitz BE, Gross M, Agus DB, Society of Behavioral Medicine
EMD121974 (NSC 707544, cilengitide) in asymptomatic metastatic androgen independent prostate cancer (AIPCa) patients (pts): A randomized trial by the Prostate Cancer C...
Bradley, D., Dunn, R., Ryan, C., DiPaola, R., Smith, D., Cooney, K., Mathew, P., Gross, M., Colevas, A., Hussain, M, Proc. Amer. Soc. of Clin. Oncol, Abstract 5137
A longitudinal assessment of treatment-related differences in quality of life among prostate cancer patients.
Giedzinska-Simons, A., Christie,K., Meyerowitz, B., Gross, M., Agus, D.B, Proc. Amer. Soc. of Clin. Oncol, Abstract 15605
Biomarkers and obesity in surgically treated patients with prostate cancer.
Gross, M., Bharne, A., Nepomuceno, E., Mirocha, J., Ramirez, D., Luthringer, D, Holden, S., Agus, D., Gross, M, Proc. Amer. Soc. of Clin. Oncol, Abstract 14536
A phase 2 trial of AP23573, an mTOR inhibitor, in patients with taxane-resistant androgen-independent prostate cancer.
Gross, M.E., Amato, R.J., Mushtaq, M., Wilding, G., Bubley, G., Trudeau, C., Rivera, V.M.. Bedrosian, C.L., Agus, D.B, European Journal of Cancer 4S:112
Obesity, Ethnicity, and Surgical Outcomes for Clinically Localized Prostate Cancer.
Gross, M., Jo, S., Huang, D., Mirocha, J., Shazer, R., Holden, S., Agus, D, Proc. Amer. Soc. of Clin. Oncol, Abstract 9615
A randomized phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane-refractory hormone refractory prostate cancer.
Rosenberg, J.E., Kelly, W.K., Michaelson, D., Wilding, G., Hussain, M., Gross, M., Weinberg, V., Small, E.J, Proc. Amer. Soc. of Clin. Oncol, Abstract 4566
Rare mutations of the PIK3CA gene in a number of cancer types and discovery of a PI3KCA pseudogene.
Muller, C., Miller, W, Gross, M., Walsh, C., Kawamata, N., Koeffler, P, Proc. Amer. Assoc. Cancer Research, Abstract 1016
A Proteomic Approach to Identify Whole Proteins Induced by Androgens, Estradiol, and IL-6 in prostate cancer cells.
Top, I., Katz, J., Damoiseaxu, R., Agus, D., Gross, M, Proc. Amer. Assoc. Cancer Research, Abstract 3095
Raloxifene, a selective estrogen receptor modulator, for the treatment of androgen independent prostate cancer (AIPC).
Cinman, N., Aronson, N., Shazer, R., Nguyen, K.N., Nguyen, H.H.T., Bender, L., Green, L., Gross, M., Kaplan, L.M., Natale, R. B., Agus, D.B, ASCO Molecular Therapeutics Symposium. Abstract #80
Join now to see all

Lectures

Laboratory Update on Prostate Cancer.
Prostate Cancer National Conference, Washington, D.C
Hematology-Oncology Grand Rounds.
Cedars Sinai Medical Center, Los Angeles, California
Drug Development Series, Targeted Bone Therapy for Prostate Cancer.
UT San Antonio Health Sciences Cente
Update on Prostate Cancer.
Los Angeles, California, 2007, 2008
Medicine Noon Conference, Prostate Cancer Overview.
Resident Teaching Noon Conference, Los Angeles, California
Obesity and Prostate Cancer.
CSMC Endocrine Grand Rounds, Los Angeles, California
Novel Therapies for Prostate Cancer.
PCRI Regional Conference, Los Angeles, California
Prostate Cancer Patient Education Series: Focus on Advanced Disease.
Los Angeles, California
Zone of Proximal Development:What Prostate Oncology Can Learn from Breast Oncology & Related Fields.
CSMC Hematology-Oncology Grand Rounds, Los Angeles, California
Bench to Bedside for Prostate Cancer.
Wellness Community, Westlake Village, California
Update on Prostate Cancer Therapy.
USTOO Support Group, Long Beach, California, 2002, 2004
Treatment for Rising PSA.
CSMC Urology Day, Los Angeles, California
ASCO 2004 Review: Prostate.
CSMC, Los Angeles, California
Hormonal Therapy for Prostate Cancer.
CSMC Endocrinology Grand Rounds, Los Angeles, California
Clinical Trials for Prostate Cancer.
CSMC Oncology Grand Rounds, Los Angeles, California
Prostate Cancer Overview.
Oncology Training Institute, New York, NY
Prostate Cancer Chemotherapy.
Prostate Cancer Research Institute, Los Angeles, California
Update on Chemotherapy for Prostate Cancer.
CSMC Oncology Grand Rounds, Los Angeles, California
Targeted Therapy for Prostate Cancer.
Wellness Community, Santa Monica, California
Join now to see all